Why the study?
To summarize the latest findings on the role of MARK4 in the pathogenesis of atherosclerosis to provide a rationale for future investigation and therapeutic intervention.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
MARK4 emerges as a potential therapeutic target in atherosclerosis; leaves open whether its modulation improves clinical outcomes.
Microtubule affinity regulating kinase 4 (MARK4), an important member of the serine/threonine kinase family, regulates the phosphorylation of microtubule-associated proteins and thus modulates microtubule dynamics. In human atherosclerotic lesions, the expression of MARK4 is significantly increased. Recently, accumulating evidence suggests that MARK4 exerts a proatherogenic effect via regulation of lipid metabolism (cholesterol, fatty acid, and triglyceride), inflammation, cell cycle progression and proliferation, insulin signaling, and glucose homeostasis, white adipocyte browning, and oxidative stress. In this review, we summarize the latest findings regarding the role of MARK4 in the pathogenesis of atherosclerosis to provide a rationale for future investigation and therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: